Gallium-68 NODAGA-JR11 PECT/CT in Neuroendocrine Tumors
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
NODAGA-JR11 is a novel somatostatin receptor antagonist, while Gallium-68 DOTATATE is a
typical somatostatin receptor agonist. This study is to evaluate the lesion detection ability
of Gallium-68 NODAGA-JR11 for the diagnostic imaging of metastatic, well-differentiated
neuroendocrine tumors using positron emission tomography / computed tomography (PET/CT).
The results will be compared between antagonist Gallium-68 NODAGA-JR11 and agonist Gallium-68
DOTATATE in the same group of patients.
Phase:
Early Phase 1
Details
Lead Sponsor:
First Affiliated Hospital of Fujian Medical University